UPC Universe Pharmaceuticals Inc

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2025

 

Commission file number: 001-40231

 

Universe Pharmaceuticals INC

 

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

Adjournment of Extraordinary General Meeting

 

On March 1, 2025, Universe Pharmaceuticals INC (the “Company”) convened an extraordinary general meeting of shareholders (the “March 2025 Extraordinary General Meeting”). However, due to lack of quorum, the March 2025 Extraordinary General Meeting was adjourned to March 8, 2025, at 10:00 a.m., Beijing Time at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji’an City, Jiangxi 343100, the People’s Republic of China.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	Universe Pharmaceuticals INC.
Date: March 3, 2025	By:	/s/ Gang Lai
		Gang Lai
		Chief Executive Officer

 

 

2

---